Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Urban Data Spaces for Green dEal (USAGE)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Food, Bioeconomy Natural Resources, Agriculture and Environment
Theme: Bio-Environment
Destination: Innovative governance, environmental observations and digital solutions in support of the Green Deal
Action type: Innovation actions
Countries involved: Spain,Austria,Italy,Netherlands,Belgium
Call: Common European Green Deal data space to provide more accessible and exploitable environmental observation data in support of the European Green Deal priority actions (HORIZON-CL6-2021-GOVERNANCE-01, 2021)
Start date: 2022-08-01
End date: 2025-07-31
Duration (months): 36.0
Total project cost (EUR): 4122544.64
EU funding (EUR): 3692800.0
Participants: 13
Project status: SIGNED

USAGE (Urban Data Space for Green Deal) aims to provide solutions and mechanisms for making city-level environmental and climate data available to everyone based on FAIR principles. USAGE will support the implementation of the European strategy for data and various European Green Deal priority actions at the level where climate change is mostly felt: cities and towns. USAGE will provide innovative governance mechanisms, consolidated arrangements, AI-based tools and data analytics to share, access and use city-level data from Earth Observation (EO), Internet of Things (IoT), authoritative and crowd sources, leveraging on standards for data and service interoperability. USAGE wants to become a decentralized infrastructure for trustworthy data collection, processing and exchange based on commonly agreed principles, facilitating the combination of heterogeneous data for policy analysis. USAGE will validate its solutions in four diverse pilot areas located in four different countries, focusing also on the reusability of the solutions in other urban areas. The consortium consists of 11 interdisciplinary partners from 5 European countries and, within the 3 years of activities, will also realize a long-term sustainability and growth strategy plan of project solutions.

Keywords: urban data space,local green data space
Force-free microstructures host intrinsic dynamics of orbital phases in AV3Sb5 Kagome metals (Free-Kagome)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Condensed Matter Physics
Panel description: Structure, electronic properties, fluids, nanosciences, biological physics
Countries involved: Germany
Call: ERC STARTING GRANTS (ERC-2024-STG, 2024)
Start date: 2025-01-01
End date: 2029-12-31
Duration (months): 60.0
Total project cost (EUR): 1500000.0
EU funding (EUR): 1500000.0
Participants: 1
Project status: SIGNED

Electron correlations significantly modify electron self-organization in quantum materials, resulting in a landscape of competing orders and exotic quantum phenomena. The recently discovered AV3Sb5 family Kagome superconductors is an intriguing example of competing correlated orders with robust entanglement, as manipulating one order can affect or modify another, akin to the unique electromagnetic responses of multi-ferroics. These strongly entangled orders have led to an exciting hypothesis of orbital loop current, a prime example of correlation-driven electronic instabilities. Nevertheless, it renders the inherent characteristics practically inaccessible through conventional means, as even slight variations in experimental conditions can significantly affect their physical properties. Our research plan is to examine the novel electronic response of the hypothesized orbital loop current in AV3Sb5. We will research the intrinsic dynamics of orbital phases and their unique electronic response via 1) atomically engineering the Kagome nets with the comprehensive material database serves as the Kagome toolbox, 2) heat/electric quenching of charge order for effectively tuning the interlayer coupling in a Kagome glass state, 3) spatial control of chiral domains with optical polarization, representing three unambiguous routes for revealing the intrinsic electronic orders in AV3Sb5. These goals are ambitious yet entirely realizable: Free-Kagome’s research approach is based on a unique force-free setup that features controllable mechanical and thermal coupling between the focused-ion-beam (FIB) fabricated microstructure and its supporting frame based on the extremely soft membrane springs with designed geometry.
Developing a Capture-Based Biomarker Assay Using cfDNA Methylation to Detect High-Risk Atherosclerotic Plaques in the Circulation (U-BiomarCAPTURE)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Netherlands
Call: ERC PROOF OF CONCEPT GRANTS (ERC-2024-POC, 2024)
Start date: 2025-06-01
End date: 2026-11-30
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: SIGNED

The holy grail in cardiology is to identify high-risk atherosclerotic plaques that may cause a myocardial infarction. This is especially relevant for women, who often experience misdiagnosis or delays in the diagnosis of coronary artery disease. Current diagnostic methods are invasive, expensive, and fail to provide precise and timely insights into the state of the plaque. The U-BiomarCAPTURE approach builds on insights from the ERC CoG UCARE and ERC PoC U-BiomarCARE projects, where we identified sex-specific differences in plaque gene regulation and detected plaque-specific DNA methylation signals in cfDNA. U-BiomarCAPTURE project aims to create a more sensitive and scalable method for detecting high-risk plaques in cardiovascular patients, significantly reducing the likelihood of missing cases. U-BiomarCAPTURE is a blood-based biomarker assay designed to predict the presence of high-risk plaques (erosion or rupture) in both female and male patients presenting with signs and symptoms of ischemia. The key advantage of our blood-based marker over imaging techniques is that it does not require patients to be sent to the hospital, offering significant benefits in an overloaded healthcare system. Our development of the first biomarker assay for predicting high-risk plaques will represent a breakthrough in cardiovascular care. This innovation is a potential game changer for the healthcare sector, enabling the specific and timely detection of dangerous atherosclerotic plaques.
Unraveling the dark matter of infectious diseases, environmental and genetic factors tipping the balance towards NCDs (ID-DarkMatter-NCD)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Health
Destination: Tackling diseases and reducing disease burden
Action type: Research and Innovation actions
Countries involved: Austria,France,Switzerland,Netherlands,Germany,Hungary,Sweden,Spain
Call: Relationship between infections and non-communicable diseases (HORIZON-HLTH-2023-DISEASE-03, 2023)
Start date: 2024-01-01
End date: 2028-12-31
Duration (months): 60.0
Total project cost (EUR): 7185870.0
EU funding (EUR): 7185361.0
Participants: 12
Project status: SIGNED

While it is known that post-COVID-19-condition (PCC) is caused by SARS-CoV-2 infection, for most other immune-related noncommunicable diseases (IR-NCDs), no such infectious disease (ID) triggers have been identified (yet). Many IDs exist that could potentially cause IR-NCDs, however these microbes have large genomes encoding many antigens possibly associated with IR-NCDs. Given that it is challenging to measure all these 100,000s of structures in parallel, they represent the dark matter of ID-immune interactions. Furthermore, exposure to an ID alone typically does not trigger development of an IR-NCD: For example only a subset of patients infected with SARS-CoV-2 develop PCC. So, genetic- and environmental aspects also affect the onset of IR-NCDs, but the exact factors are unknown for most IR-NCDs. Here, we aim to 1.) identify IDs triggering IR-NCDs by screening for antibody responses against 600,000 ID antigens, and 2.) to disentangle environmental and genetic factors affecting the transition from IDs to IR-NCDs. We will combine novel multi-omics approaches and technologies for personalized genotyping of HLA and adaptive immune receptor genes to deeply profile 6,000 patients of six IR-NCDs (PCC, multiple sclerosis, ME/CFS, rheumatoid arthritis, lupus, IBD) to identify novel biomarkers and disease mechanisms. This project will represent the largest and most deeply profiled systematic study of multiple IR-NCDs with layered datasets allowing for comparative analyses yielding insights into shared mechanisms and potential differences in the role of IDs between IR-NCDs. Building on associations identified from population scale and clinical cohorts, we will demonstrate causality in gnotobiotic mouse models, and leverage machine learning (ML) algorithms to predict disease progression and response to treatment. The combination of novel assays with ML represents a broadly applicable pipeline that can be used for studying the interplay of any other IDs/ IR-NCDs.

Keywords: machine learning,antibody repertoires,hla genotyping,bcr tcr germline variation,microbiota immune axis
Deciphering context-dependent roles of oncogenic gene fusions in vivo (FusionTRACE)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Physiology in Health, Disease and Ageing
Panel description: Organ and tissue physiology, comparative physiology, physiology  of ageing , pathophysiology, inter - organ and tissue communication, endocrinology, nutrition,  metabolism, interaction with the microbiome, non -communicable diseases including cancer (and except disorders of the nervous system  and immunity -related diseases)
Countries involved: Germany
Call: ERC CONSOLIDATOR GRANTS (ERC-2024-COG, 2024)
Start date: 2025-04-01
End date: 2030-03-31
Duration (months): 60.0
Total project cost (EUR): 1999863.0
EU funding (EUR): 1999863.0
Participants: 1
Project status: SIGNED

Sarcomas are an extremely heterogeneous group of mesenchymal cancers, many of which remain lethal despite decades of clinical trials. A unifying characteristic in pediatric sarcomas is their low mutational burden. Instead, they frequently harbor an entity-specific chromosomal rearrangement giving rise to an oncofusion protein that acts as the disease driver. This genetic simplicity underlying a complex group of tumors implies a synergy between oncofusions and the cellular context in which they occur. However, the cell-of-origin for the vast majority of sarcomas is unknown. We have developed a flexible method for somatic engineering of the mouse muscle to model more than 10 genetically distinct pediatric sarcoma subtypes. Here we will take advantage of this unique tool to understand key questions so far unanswered due to the lack of suitable sarcoma models and flexible genetic approaches: 1.What is the identity of the cell(s) of origin and why are they permissive to transformation? 2.Are gene fusions required for tumor maintenance? And if they are, to what extent is transformation reversible? Do tumor cells retain memory of their previous normal states? Or there is a point of no return when they forget what they used to be? By combining our models with transgenic mouse lines that allow in vivo cell barcoding, we will trace, isolate and characterize different population of cells in normal muscle and in primary tumors to identify and study sarcoma cells-of-origin. To understand the role of gene fusions in tumor maintenance we will apply the degradation system (dTAG) for in vivo acute degradation of oncofusion proteins. Temporal and spatial analysis will allow to dissect complex biological responses to oncogene withdrawal. These approaches will combine cutting-edge technologies to provide fundamental knowledge on the mechanisms underlying tumorigenesis, their intertwining with existing cellular states and the potential of oncofusion withdrawal for sarcoma treatment.

Keywords: pediatric solid tumors,sarcoma,in vivo cell barcoding,lineage tracing,targeted protein degradation
Redefine energy Efficiency solutions for hydrogen powered SHIPs in marine and inland waterway (RESHIP)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Climate, Energy and Mobility
Theme: Mobility
Destination: Clean and competitive solutions for all transport modes
Action type: Research and Innovation actions
Partnership: ZEWT (co-programmed)
Countries involved: France,Denmark,United Kingdom,Netherlands,Sweden,Germany,Italy,Greece,Cyprus
Call: Innovative on-board energy saving solutions (ZEWT Partnership) (HORIZON-CL5-2021-D5-01, 2021)
Start date: 2022-09-01
End date: 2026-04-30
Duration (months): 44.0
Total project cost (EUR): 3805478.75
EU funding (EUR): 3758912.5
Participants: 15
Project status: SIGNED

Under the framework of Zero Emission Waterborne Transport (ZEWT), hydrogen as the future fuel for ships offers an opportunity to zero the GHG emission. Nevertheless, the challenges for onboard hydrogen storage and utilisation obstruct this long desired revolution. Novel and effective technology solution is urgently needed. The project, RESHIP, aims to redefine the onboard energy saving solutions for newbuilds and retrofits in marine and inland waterway with disruptive technologies in two distinct areas, Energy Saving Devices (ESDs) and onboard hydrogen utilisation. Regarding the ESDs, the project proposes to research and develop hydrogen compatible ESD solutions in standalone/combined applications, centered around Tubercle Assisted Propulsors (TAPs), to improve the vessel's propulsive energy efficiency and to optimise towards hydrogen power and drive system. With the novel and energy efficient hydrogen carrier technology HydroSil, RESHIP links the ESD technology to the research of the energy efficient onboard hydrogen utilisation technology to systematically reshape the hydrogen driven ships with a holistic energy saving solution. Together, RESHIP aims to achieve a minimum overall 35% energy saving and to half the hydrogen storage demands on space and/or weight, comparing to the state-of-the-art hydrogen powered vessels. The proposal responds to the Horizon Europe Research and Innovation Action call on the topic “Innovative on-board energy saving solutions” (ID: HORIZON-CL5-2021-D5-01-10). The consortium gathers world-leading multidisciplinary experts and key patent holders with 13 partners from 9 EU countries, forging a complementary stakeholder group. The consortium covers two industrial sectors, shipping and ships together with hydrogen. The implementation of the developed technologies will be demonstrated and validated in technical, environmental, cost economical, safety and regulatory levels, bringing TRL from 2-3 to 5-6.

Keywords: hydrogen powered vessel energy saving devices hydrosil tubercle assisted propulsion
Scalable processing of highly stable, flexible multi-junction perovskite solar cells from green inks (GreenPeroInk)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Physics
Countries involved: Germany
Call: MSCA Postdoctoral Fellowships 2023 (HORIZON-MSCA-2023-PF-01, 2023)
Start date: 2025-07-31
End date: 2027-07-30
Duration (months): 24.0
Total project cost (EUR): 173847.36
EU funding (EUR): 173847.36
Participants: 1
Project status: SIGNED

This proposal develops perovskite solar cells (PSCs) as a transformative power conversion technology by addressing critical challenges related to stability and scalability. The key objectives are: 1: Translate a low-toxicity precursor ink and 2D-templated crystallisation method, recently developed by the Applicant, from laboratory-scale to scalable manufacturing processes. Use this method to produce flexible, single-junction PSCs with >20% efficiency, compatible with lightweight Internet of Things applications. 2: Explore 2D-templated fabrication of a range of complex, mixed-ion halide perovskites with bandgaps ranging from 1.2-2.0 eV. Using a combinatorial slot-die coating approach pioneered by the Host group, high-throughput ink and process optimization will be achieved, followed by in-depth investigation and enhancement in compositional stability of the perovskite phases formed. Having optimised single-junction cells of relevant bandgaps, multi-junction devices will be scalably fabricated. 3: Recognizing that degradation in PSCs often occurs at interfaces between the perovskite layer and adjacent materials in the cell, conduct a systematic investigation to understand and mitigate degradation mechanisms in our single- and multi-junction PSCs. Employing luminescence mapping we will first spatially identify interfacial instabilities evolving in PSCs under operational aging. Having identified stability-limiting interfaces, solid-state nuclear magnetic resonance spectroscopy and time-of-flight secondary ion mass spectrometry 3D mapping will allow us to analyse interface degradation at the atomic level, providing mechanistic insights into active degradation pathways. Based on this investigation, a tailored range of stability enhancement strategies will be used to enhance PSC stability. With these objectives, this proposal will advance commercial implementation of PSC technologies, paving the way for more efficient, cost-effective, secure and renewable energy solutions.

Keywords: metal halide perovskites scalable processing green processing
Development of human 3D organoid model of Alzheimer's disease (MIND-AD)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Finland
Call: MSCA Postdoctoral Fellowships 2024 (HORIZON-MSCA-2024-PF-01, 2024)
Start date: 2026-01-01
End date: 2027-12-31
Duration (months): 24.0
Total project cost (EUR): 242116.8
EU funding (EUR): 242116.8
Participants: 1
Project status: SIGNED

Alzheimer’s disease (AD) is the leading cause of dementia, affecting over 50 million people worldwide. Characterized by memory loss, cognitive decline, and the formation of amyloid-β plaques and neurofibrillary tangles, AD presents a significant global health burden. Current AD models, particularly in mice, fail to accurately represent the sporadic form of human AD, limiting the translation of research into effective treatments. Human-induced pluripotent stem cells (hiPSCs) offer a promising alternative for creating in vitro models, but these often lack key features of AD pathology and immune cell interactions. This project aims to develop a 3D organoid model for sporadic AD. We will use nanoparticles as nucleation seeds to facilitate amyloid aggregation from AD patient brain extracts, allowing a more faithful representation of AD pathology. By incorporating microglia into the model, we aim recapitulate human-specific microglial states in AD. By analyzing organoids with and without microglia, we will be able to investigate whether and how microglia contribute to initiation and progression of AD-related pathology, thus providing insights into this so far unanswered question in the field. We will compare all obtained readouts to idiopathic normal pressure hydrocephalus patient brain biopsies, that contain early AD-related pathology, thus verifying that our model is able to recapitulate features of human AD brain. This innovative approach will address the limitations of current models by integrating both neuronal and immune components, offering a more comprehensive platform for studying AD and testing potential therapies. Overall, the project has the potential to advance our understanding of AD mechanisms and contribute to the development of more effective treatments.

Keywords: alzheimer s disease,microglia,cortical organoid,ipscs,proteomics,nanoparticle,amyloid beta
Beta-Lactamase Inhibitors Synthesised through in Situ click chemistry (BLISS)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Italy,United States
Call: MSCA Postdoctoral Fellowships 2021 (HORIZON-MSCA-2021-PF-01, 2021)
Start date: 2022-10-16
End date: 2024-10-15
Duration (months): 24.0
Total project cost (EUR): 188590.08
EU funding (EUR): 188590.08
Participants: 2
Project status: CLOSED

Herein, kinetic-guided target synthesis (KTGS) will be used to discover novel boronic acids inhibitors of KPC-2, a clinically relevant serine beta-lactamase, with the aim to tackle antimicrobial resistance (AMR) and restore beta-lactams antibiotic activity. Boronic acids transition state inhibitors (BATSIs) have been extensively employed to inhibit beta-lactamases, a class of bacterial enzymes responsible for the most widespread mechanism of AMR against beta-lactam antibiotics. However, the structural variety characterizing the different types of beta-lactamases imposes the development of novel beta-lactamases inhibitors (BLIs). To fully exploit the potential of BATSIs as antibacterial agents and expedite the drug development process, KTGS will be used as a platform for drug discovery. KTGS is an innovative strategy where the biological target is employed to catalyze the synthesis of its own best effective inhibitors from a library of reagents. Triazole-based BATSIs, which have been reported to be potent and selective inhibitors of KPC-2, will be generated in a rapid and efficient way through KTGS (in situ click chemistry). Given the strong interaction between BATSIs and their targets, KPC-2 will be employed as scaffold for the formation of potent and selective 1,4-disubstitued triazole-based BATSIs, starting from azido boronic acid warheads and functionalized alkynes. In summary, this proposal seeks the development of novel BLIs drug candidates through the accomplishment of three objectives: 1) Investigation of KPC-2 as scaffold for in situ click chemistry and evaluation of the ability to generate triazole-based BATSI; 2) Discovery of novel inhibitors for KPC-2 using KTGS; 3) Identification of at least one highly active BATSI against clinically relevant beta-lactamases to be tested in vivo. To accomplish these specific objectives, the project will be divided in three main work packages, which will involve a combination of biological, chemical, and analytical skills

Keywords: in situ click chemistry,antimicrobial resistance,boronic acids,beta lactamase inhibitor,kinetic guided target synthesis kgts